mTOR pathway gene mutations predict response to immune checkpoint inhibitors in multiple cancers.

These results suggested that mTOR pathway gene mutations were predictive of better survival upon ICI treatment in multiple cancers, likely by its association with enhanced anti-tumor immunity. Larger studies are warranted to validate our findings.